Novel Fusion Proteins of Interferon α2b Cause Growth Inhibition and Induce JAK-STAT Signaling in Melanoma

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of immunotherapy

• Publication date

  2010-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/CJI.0b013e3181d32e59PMID 20463602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• On the discovery of interferon-inducible, double-stranded RNA activated enzymes: the 2'-5'oligoadenylate synthetases and the protein kinase PKR.

  2007influential reference
• High-yields and extended serum half-life of human interferon alpha2b expressed in tobacco cells as arabinogalactan-protein fusions.

  2007cited by this paper
• The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation.

  2007cited by this paper
• Interferon, a growing cytokine family: 50 years of interferon research.

  2007cited by this paper
• Interferons at age 50: past, current and future impact on biomedicine

  2007cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Site-directed PEGylation of human basic fibroblast growth factor.

  2006cited by this paper
• Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

  2006cited by this paper
• GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

  2006cited by this paper
• PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.

  2005cited by this paper
• Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.

  2005cited by this paper
• Interferons, interferon‐like cytokines, and their receptors

  2004cited by this paper
• Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification*

  2004cited by this paper
• The JAK/STAT signaling pathway

  2004cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.

  2003cited by this paper
• Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity

  2003cited by this paper
• Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.

  2002cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• Synthetic genes for the elucidation of glycosylation codes for arabinogalactan-proteins and other hydroxyproline-rich glycoproteins

  2001cited by this paper
• Interferon‐α delays S‐phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin‐dependent kinases

  2001cited by this paper
• Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.

  2001cited by this paper
• Mechanisms of interferon-induced cell cycle arrest.

  2000cited by this paper
• Defective Jak‐STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon‐α

  2000cited by this paper
• Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.

  2000cited by this paper
• Expression of the JAK and STAT superfamilies in human meningiomas.

  1999cited by this paper
• The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.

  1999cited by this paper
• Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.

  1998influential reference
• Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase.

  1998cited by this paper
• Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3γ*

  1997influential reference
• Distinct STAT Structure Promotes Interaction of STAT2 with the p48 Subunit of the Interferon-α-stimulated Transcription Factor ISGF3*

  1997cited by this paper
• Interferon signal transduction

  1996cited by this paper
• Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.

  1996influential reference
• Coiled coils: new structures and new functions.

  1996cited by this paper
• Predicting coiled coils by use of pairwise residue correlations.

  1995cited by this paper
• Transcriptional responses to polypeptide ligands: the JAK-STAT pathway.

  1995cited by this paper
• Cancer statistics

  1989cited by this paper
• Inhibition of cell division by interferon: changes in cell cycle characteristics and in morphology of Ehrlich ascites tumour cells in culture.

  1981cited by this paper
• Block of a glioma cell line in S by interferon

  1981cited by this paper
• Isolation of two interferon-induced translational inhibitors: a protein kinase and an oligo-isoadenylate synthetase.

  1978cited by this paper

• The JAK2/STAT3 pathway is involved in the anti-melanoma effects of brevilin A.

  2019cites this paper
• Hypothalamic Glial Cells in Diet Induced Obesity

  2015cites this paper
• Signal transduction in human cutaneous melanoma and target drugs.

  2013cites this paper
• Enhanced accumulation of secreted human growth hormone by transgenic tobacco cells correlates with the introduction of an N-glycosylation site.

  2011cites this paper
• Investigating the role of novel fusion proteins of interferon in melanoma

  2010cites this paper